Moderna to Present Pivotal Phase 3 Cancer Vaccine Trial Results at ESMO Presidential Symposium

Moderna is scheduled to release the full Phase 3 trial data for its therapeutic cancer vaccine, mRNA-4157 (V940), in combination with Merck's Keytruda, for melanoma. The presentation at the European Society of Medical Oncology (ESMO) Presidential Symposium is highly anticipated, suggesting the potential for the findings to influence the standard of care for cancer treatment.